A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases

Eric Marks, Syed Mujtaba Rizvi, Nabeel Sarwani, Zhaohai Yang, Wafik S. El-Deiry

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We present the case of a 43-year-old-man with wild-type KRAS and BRAF colorectal adenocarcinoma that was metastatic to the liver and lung. The patient initially received neoadjuvant chemotherapy with FOLFOX and bevacizumab, followed by surgical resection of the primary tumor and hepatic metastases. His disease recurred shortly after surgery and he was treated with FOLFIRI plus the anti-EGFR antibody cetuximab. After this regimen failed to arrest his disease progression, treatment with FOLFIRI in combination with another anti-EGFR antibody, panitumumab was started. While on this therapy, the patient's lung nodules remained largely stable but metastatic lesions within the liver continued to progress. Our case highlights the differences between panitumumab and cetuximab, and contemplates the possible explanations for this patient's apparently heterogeneous disease progression within the liver despite stabilization of multiple pulmonary nodules.

Original languageEnglish (US)
Pages (from-to)377-382
Number of pages6
JournalCancer Biology and Therapy
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Adenocarcinoma
Neoplasm Metastasis
Liver
Disease Progression
Anti-Idiotypic Antibodies
Multiple Pulmonary Nodules
Lung
Drug Therapy
panitumumab
Cetuximab
Therapeutics
Neoplasms

Keywords

  • Cetuximab
  • Metastatic colorectal adenocarcinoma
  • Panitumumab
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. / Marks, Eric; Rizvi, Syed Mujtaba; Sarwani, Nabeel; Yang, Zhaohai; El-Deiry, Wafik S.

In: Cancer Biology and Therapy, Vol. 16, No. 3, 01.03.2015, p. 377-382.

Research output: Contribution to journalArticle

Marks, Eric ; Rizvi, Syed Mujtaba ; Sarwani, Nabeel ; Yang, Zhaohai ; El-Deiry, Wafik S. / A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. In: Cancer Biology and Therapy. 2015 ; Vol. 16, No. 3. pp. 377-382.
@article{53278ed6134e4459a7bab2d71ac4c6ec,
title = "A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases",
abstract = "We present the case of a 43-year-old-man with wild-type KRAS and BRAF colorectal adenocarcinoma that was metastatic to the liver and lung. The patient initially received neoadjuvant chemotherapy with FOLFOX and bevacizumab, followed by surgical resection of the primary tumor and hepatic metastases. His disease recurred shortly after surgery and he was treated with FOLFIRI plus the anti-EGFR antibody cetuximab. After this regimen failed to arrest his disease progression, treatment with FOLFIRI in combination with another anti-EGFR antibody, panitumumab was started. While on this therapy, the patient's lung nodules remained largely stable but metastatic lesions within the liver continued to progress. Our case highlights the differences between panitumumab and cetuximab, and contemplates the possible explanations for this patient's apparently heterogeneous disease progression within the liver despite stabilization of multiple pulmonary nodules.",
keywords = "Cetuximab, Metastatic colorectal adenocarcinoma, Panitumumab, Targeted therapy",
author = "Eric Marks and Rizvi, {Syed Mujtaba} and Nabeel Sarwani and Zhaohai Yang and El-Deiry, {Wafik S.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1080/15384047.2015.1004927",
language = "English (US)",
volume = "16",
pages = "377--382",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases

AU - Marks, Eric

AU - Rizvi, Syed Mujtaba

AU - Sarwani, Nabeel

AU - Yang, Zhaohai

AU - El-Deiry, Wafik S.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - We present the case of a 43-year-old-man with wild-type KRAS and BRAF colorectal adenocarcinoma that was metastatic to the liver and lung. The patient initially received neoadjuvant chemotherapy with FOLFOX and bevacizumab, followed by surgical resection of the primary tumor and hepatic metastases. His disease recurred shortly after surgery and he was treated with FOLFIRI plus the anti-EGFR antibody cetuximab. After this regimen failed to arrest his disease progression, treatment with FOLFIRI in combination with another anti-EGFR antibody, panitumumab was started. While on this therapy, the patient's lung nodules remained largely stable but metastatic lesions within the liver continued to progress. Our case highlights the differences between panitumumab and cetuximab, and contemplates the possible explanations for this patient's apparently heterogeneous disease progression within the liver despite stabilization of multiple pulmonary nodules.

AB - We present the case of a 43-year-old-man with wild-type KRAS and BRAF colorectal adenocarcinoma that was metastatic to the liver and lung. The patient initially received neoadjuvant chemotherapy with FOLFOX and bevacizumab, followed by surgical resection of the primary tumor and hepatic metastases. His disease recurred shortly after surgery and he was treated with FOLFIRI plus the anti-EGFR antibody cetuximab. After this regimen failed to arrest his disease progression, treatment with FOLFIRI in combination with another anti-EGFR antibody, panitumumab was started. While on this therapy, the patient's lung nodules remained largely stable but metastatic lesions within the liver continued to progress. Our case highlights the differences between panitumumab and cetuximab, and contemplates the possible explanations for this patient's apparently heterogeneous disease progression within the liver despite stabilization of multiple pulmonary nodules.

KW - Cetuximab

KW - Metastatic colorectal adenocarcinoma

KW - Panitumumab

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84926379181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926379181&partnerID=8YFLogxK

U2 - 10.1080/15384047.2015.1004927

DO - 10.1080/15384047.2015.1004927

M3 - Article

C2 - 25695537

AN - SCOPUS:84926379181

VL - 16

SP - 377

EP - 382

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -